PixarBio Corporation, developers of NeuroRelease™NR14, a 14-day post-surgical pain treatment, clarifies its position on NR14 treating “Trigeminal Neuralgia” and post-surgical pain. The post-surgical pain market exceeds 90,000,000 surgeries per year. Trigeminal Neuralgia is a fragmented market, but it is believed to effect between 65,000 - 275,000 patients living in the USA. The company believe clinical studies will prove that NR14 will safely provide benefit to both severe pain conditions TN and PSP so intend to file two separate NDA’s. The copany intend to file a US FDA NDA in late 2019 for NR14 to treat the estimated 90,000,000+ annual post-surgical pain (PSP) patients in the USA. The company also intend to file an NDA in early 2020 for NR14 to treat Trigeminal Neuralgia. According to NIH’s National Institute of Neurological Disorders & Stroke (NINDS) Trigeminal neuralgia (TN), also called tic douloureux, is a chronic pain condition that affects the trigeminal or 5th cranial nerve, one of the most widely distributed nerves in the head. TN is a form of neuropathic pain often associated with nerve injury or nerve lesion. NeuroRelease™ is a morphine replacement, and non-addictive pain platform for post-surgical pain. First product FDA approval is anticipated in late 2019 for a 14-day post-surgical pain treatment.